Abstract
It is a public health priority the development of a novel vaccine and new therapeutic agents against Tuberculosis (TB) due to the enormous impact of this pathology worldwide (WHO, 2005). In this sense, we work in a DNA vaccine encoding the 65 kDa heat shock protein of Mycobacterium leprae (DNA-HSP65) and various reports of our laboratory had shown that this vaccine has prophylactic (Lowri…